Colgate-Palmolive Company, a global leader in oral care and consumer products, has seen its stock decline 18.2% over the past year, reflecting challenges in key markets. Analysts expect a 1.7% increase in EPS for fiscal year 2025. The stock holds a consensus “Moderate Buy” rating, with a mean price target of $88.09.

JPMorgan recently lowered its price target on CL to $88, citing weaker category performance. The mean price target suggests a potential 15.1% upside, while the Street-high price target of $100 implies a 30.6% upside. Analysts remain cautious given the company’s current challenges and uncertainties.

Read more at Yahoo Finance: What Are Wall Street Analysts’ Target Price for Colgate-Palmolive Company Stock?